Boehringer Ingelheim grants Gilead Sciences exclusive, worldwide rights to non-catalytic site integrase inhibitors to treat HIV

Boehringer Ingelheim GmbH

Germany / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Gilead Sciences Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$30,325.9m on 10/07/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced